🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Elegant presentation on alternative lenghtening of telomerase in #sarcoma PDXs by Aga Wozniak #CTOS2024 CTOS #cTOSTweeTOS

Great research on SDH-deficient #GIST from UC San Diego Health Moores Cancer Center on DR-5 agonist INBRX-109 in combination with TMZ #CTOS2024 looking forward to future trial with this combo

The Nina Axelrad lecture by Bob Maki of Sarcoma Service at Memorial Sloan Kettering CTOS #CTOS2024

Thank you #CTOS2024 organizing committees for the opportunity to present our project on uncovering fusion oncoprotein-specific #E3ligases for #TPD approaches, performed by our MD candidate Kilian Bales in collab with Mikołaj Słabicki @seppobauer Dominic Helm & team DKFZ Proteomics Core

Brian Van Tine presenting the results of SUNRISELMS trial of unesbulin+dacarbazine ❌study was closed prematurely at the interim analysis but there are signals of efficacy CTOS #CTOS2024 #CTOSTweeTOS

David Kirsch, MD, PhD presenting the results of SARC032 trial, favoring addition of pembrolizumab to preoperative radiotherapy & surgery, & improved disease-free survival in UPS and DDLS patients published recently in The Lancet, with a sneak peak in correlative analysis led by

#PUSH Pushing Ultra-rare Sarcomas towards Hope!

#CTOS2024 came to an end! Thank you for participating and all the social media interactions! And please save the date for the #CTOS2025 in Boca Raton to 🥳celebrate together the 🎂30th Aniversary of CTOS! #CTOSTweeTOS

Hey, watch out... here is a nice recap of the best published studies in 2023/2024 in #sarcoma Thanks to all the investigators for their great job! Annals of Surgical Oncology CTOS TARPSWG Istituto Tumori Chirurgia dei Sarcomi INT Society of Surgical Oncology European Society of Surgical Oncology (ESSO) rdcu.be/d2Sja

Amazing numbers for #ESMOAsia24 🎉. We couldn’t have done it without all the support from the #oncology community! ✨💕

Congrats! A big step in #immunotherapy for #sarcoma especially for visceral #angiosarcoma which typically unlikely to respond #ICI combinations! Looking forward to see future studies for validation!

Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study - Annals of Oncology Annals of Oncology annalsofoncology.org/article/S0923-…

It is #RareDisease Month!🦓 There are > 7,000 rare diseases & 1 in 10 Americans have a rare disease. About half of rare diseases impact children & over three-quarters of rare diseases are genetic. It’s not that rare to be rare! 1/n #ShowYourStripes #RareDiseaseAwareness

FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumor. Vimseltinib achieved a 40% ORR in #TGCT patients, significantly outperforming placebo in the MOTION trial. ⁦TGCT Support⁩ ⁦The Life Raft Group⁩ #sarcoma onclive.com/view/fda-appro…

For all #sarcoma #enthusiasts. One month to the #ATLAS #Sarcoma Webinar by Dr. Valerie Yang of #NCCS and Dr. JC Lee of #NTUH. Register and book your calendar! Look forward to seeing you online!

#JSMO25 国際展示場2号館1階の企業展示に Taiwan Oncology Society（TOS）ブースを設置しております。The 29h Taiwan Joint Cancer Conferenceもご紹介しておりますので，ぜひお立ち寄りください🧐 tjcc.tw by 事務局 （ブース近くには専門医ラウンジがあります）

📢To all CTOS #sarcoma #peeps! The #CommunicationsCommittee wants to know what YOUR preferences are when it comes to #SocialMedia. Please take a couple of minutes to fill this online survey so we can push our #messages and #interact with you in the most efficient &

Thanks to Dr. Scott Okuno for the opportunity to write the review on the #immunotherapies for #angiosarcoma. rdcu.be/ei0fV